{"id":"letrozole-oral-tablet","safety":{"commonSideEffects":[{"rate":"19-29%","effect":"Hot flashes"},{"rate":"19-25%","effect":"Arthralgia/joint pain"},{"rate":"13-18%","effect":"Fatigue"},{"rate":"7-10%","effect":"Headache"},{"rate":"7-9%","effect":"Nausea"},{"rate":null,"effect":"Osteoporosis/bone loss"},{"rate":null,"effect":"Elevated cholesterol"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Letrozole is a non-steroidal aromatase inhibitor that selectively blocks the cytochrome P450 enzyme aromatase, which catalyzes the final step of estrogen biosynthesis. By reducing estrogen levels, it suppresses the growth of estrogen-dependent breast cancer cells. This mechanism is particularly effective in postmenopausal women where aromatase is the primary source of estrogen production.","oneSentence":"Letrozole inhibits aromatase, the enzyme responsible for converting androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:43.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer in postmenopausal women"},{"name":"Adjuvant treatment of early-stage breast cancer in postmenopausal women"},{"name":"Extended adjuvant therapy following tamoxifen in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT07349069","phase":"PHASE3","title":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-04","conditions":"Breast Cancer","enrollment":4800},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT07389733","phase":"PHASE1, PHASE2","title":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-02","conditions":"Advanced Unresectable or Metastatic Breast Cancer of Adults","enrollment":180},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT05909397","phase":"PHASE3","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-09","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT04002141","phase":"PHASE2","title":"Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-09-17","conditions":"Endometriosis, Ovarian Hyperstimulation","enrollment":60},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT05860465","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-08","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":254},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT06974929","phase":"PHASE1, PHASE2","title":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-05-22","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT04603183","phase":"PHASE2","title":"ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL","status":"COMPLETED","sponsor":"MedSIR","startDate":"2021-06-02","conditions":"Breast Cancer Metastatic","enrollment":162},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT06706414","phase":"PHASE1, PHASE2","title":"NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-03-01","conditions":"Infertility, Male","enrollment":16},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT01797523","phase":"PHASE2","title":"A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-07","conditions":"Endometrial Cancer","enrollment":62},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT03822468","phase":"PHASE2","title":"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Breast Cancer","enrollment":376},{"nctId":"NCT06465368","phase":"PHASE2","title":"A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-11","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT04191382","phase":"PHASE2","title":"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-02-04","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT07168837","phase":"NA","title":"Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-01-10","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":100},{"nctId":"NCT04478266","phase":"PHASE3","title":"Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-10-14","conditions":"Breast Cancer","enrollment":1068},{"nctId":"NCT06041204","phase":"NA","title":"Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism","status":"RECRUITING","sponsor":"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy","startDate":"2021-05-06","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Subclinical Hypothyroidism, Female Infertility","enrollment":200},{"nctId":"NCT05744687","phase":"PHASE2, PHASE3","title":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-04-24","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":374},{"nctId":"NCT05872347","phase":"PHASE2","title":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-19","conditions":"Breast Cancer Brain Metastases","enrollment":52},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT06504082","phase":"NA","title":"Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole + Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2021-09-20","conditions":"Ectopic Pregnancy","enrollment":60},{"nctId":"NCT05257395","phase":"PHASE3","title":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-03-14","conditions":"Advanced Breast Cancer","enrollment":397},{"nctId":"NCT06953882","phase":"PHASE2","title":"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-07-09","conditions":"HER2 Negative Breast Cancer","enrollment":140},{"nctId":"NCT03099174","phase":"PHASE1","title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-04","conditions":"Neoplasms, Breast Neoplasms","enrollment":133},{"nctId":"NCT04614194","phase":"PHASE2","title":"Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT05206448","phase":"PHASE4","title":"Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rachel Mejia","startDate":"2020-10-26","conditions":"Polycystic Ovary Syndrome, PCOS, Infertility","enrollment":190},{"nctId":"NCT05247268","phase":"PHASE2","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-03-11","conditions":"Endometrial Neoplasm Malignant Stage I","enrollment":104},{"nctId":"NCT06861803","phase":"","title":"Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients","status":"NOT_YET_RECRUITING","sponsor":"Al-Azhar University","startDate":"2025-04-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","enrollment":138},{"nctId":"NCT05872204","phase":"PHASE2","title":"Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-11-30","conditions":"Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor","enrollment":100},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT01958021","phase":"PHASE3","title":"Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-17","conditions":"Advanced, Metastatic Breast Cancer","enrollment":668},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT05847257","phase":"PHASE2","title":"Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram","status":"COMPLETED","sponsor":"Al-Mustansiriyah University","startDate":"2021-12-01","conditions":"Male Reproductive Problem, Infertility, Male","enrollment":74},{"nctId":"NCT05166668","phase":"NA","title":"Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2021-11-01","conditions":"Ovarian Stimulation","enrollment":200},{"nctId":"NCT02661932","phase":"PHASE4","title":"Fertility Preservation in Breast Cancer Patients","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2012-11","conditions":"Breast Neoplasms, Fertility","enrollment":65},{"nctId":"NCT05601700","phase":"PHASE3","title":"Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","status":"RECRUITING","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2022-09-22","conditions":"Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary","enrollment":132},{"nctId":"NCT04321551","phase":"PHASE4","title":"Hormone Secretion in Transgender Males","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2023-07-01","conditions":"Transgender, Healthy","enrollment":""},{"nctId":"NCT04985266","phase":"PHASE2","title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2022-03-30","conditions":"ER+ Breast Cancer, HER2-negative Breast Cancer","enrollment":1100},{"nctId":"NCT03378297","phase":"EARLY_PHASE1","title":"IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2018-05-04","conditions":"Ovarian Cancer","enrollment":26},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT05163106","phase":"PHASE2","title":"Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2022-12-01","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer","enrollment":85},{"nctId":"NCT03439046","phase":"PHASE3","title":"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-02","conditions":"Breast Cancer","enrollment":287},{"nctId":"NCT03900637","phase":"PHASE2","title":"PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2019-11-08","conditions":"Breast Cancer","enrollment":122},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT06486870","phase":"PHASE3","title":"Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-01-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","enrollment":183},{"nctId":"NCT05487092","phase":"NA","title":"Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-12-01","conditions":"Endometriotic Cyst of Ovary","enrollment":194},{"nctId":"NCT06367712","phase":"PHASE1","title":"Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol","status":"COMPLETED","sponsor":"Egymedicalpedia","startDate":"2022-11-10","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","enrollment":132},{"nctId":"NCT06354439","phase":"PHASE4","title":"Use of Letrozole for Ectopic Pregnancy","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-03-27","conditions":"Ectopic Pregnancy","enrollment":130},{"nctId":"NCT00382070","phase":"PHASE3","title":"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":3966},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT03308201","phase":"PHASE1","title":"Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2017-10-16","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT06181305","phase":"PHASE4","title":"Endometrial Preparation in Frozen Embryo Transfer Cycles","status":"UNKNOWN","sponsor":"Rahem Fertility Center","startDate":"2024-02-24","conditions":"IVF","enrollment":210},{"nctId":"NCT03936270","phase":"PHASE2","title":"Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer","status":"COMPLETED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2020-03-05","conditions":"Ovarian Cancer","enrollment":43},{"nctId":"NCT06235931","phase":"NA","title":"A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Breast Neoplasms","enrollment":34},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT03122197","phase":"EARLY_PHASE1","title":"Study of Letrozole in Recurrent Gliomas","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2017-05-16","conditions":"Brain Tumor","enrollment":39},{"nctId":"NCT05705505","phase":"PHASE1, PHASE2","title":"Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies","status":"UNKNOWN","sponsor":"Traws Pharma, Inc.","startDate":"2023-03-29","conditions":"Endometrioid Endometrial Cancer","enrollment":60},{"nctId":"NCT05157672","phase":"EARLY_PHASE1","title":"Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon","status":"UNKNOWN","sponsor":"Washington State University","startDate":"2021-12-14","conditions":"Interaction Drug Food","enrollment":16},{"nctId":"NCT06047184","phase":"PHASE1","title":"Phase I Study of BEBT-209 in Women With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2019-07-15","conditions":"Advanced Breast Cancer","enrollment":106},{"nctId":"NCT05198050","phase":"NA","title":"Letrozole in Induction of Abortion of Anembryonic Pregnancy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-04-03","conditions":"Anembryonic Pregnancy","enrollment":96},{"nctId":"NCT05304273","phase":"PHASE3","title":"Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages","status":"UNKNOWN","sponsor":"Calcutta National Medical College and Hospital","startDate":"2022-05-05","conditions":"Miscarriage","enrollment":120},{"nctId":"NCT02585388","phase":"PHASE2","title":"Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.","status":"TERMINATED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2015-10-23","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT02686151","phase":"PHASE3","title":"The Letrozole Administration During Luteal Phase","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Inner Mongolia Medical University","startDate":"2023-12","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":50},{"nctId":"NCT05890287","phase":"NA","title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-16","conditions":"HR Positive HER2 Negative Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05874518","phase":"NA","title":"Clinical Observation of Warm Needling Combined With and Electroacupuncture Therapy on Ovulatory Dysfunction","status":"COMPLETED","sponsor":"Liuzhou Maternity and Child Healthcare Hospital","startDate":"2021-12-01","conditions":"Warm Needling, Electroacupuncture, Ovulation Dysfunction","enrollment":70},{"nctId":"NCT01698918","phase":"PHASE2","title":"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-07","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":202},{"nctId":"NCT03458221","phase":"PHASE2, PHASE3","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","status":"RECRUITING","sponsor":"Gynaecologisch Oncologisch Centrum Zuid","startDate":"2023-01-31","conditions":"Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer","enrollment":148},{"nctId":"NCT04341545","phase":"PHASE3","title":"Letrozole in Tubal Ectopic Pregnancy","status":"UNKNOWN","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2020-12-01","conditions":"Tubal Pregnancy","enrollment":214},{"nctId":"NCT05792410","phase":"PHASE1, PHASE2","title":"A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-04","conditions":"HER2 Low Advanced or Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT02894398","phase":"PHASE2","title":"Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-09-06","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":388},{"nctId":"NCT04193930","phase":"NA","title":"Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles","status":"WITHDRAWN","sponsor":"Assiut University","startDate":"2021-01-01","conditions":"ART","enrollment":""},{"nctId":"NCT02679755","phase":"PHASE4","title":"Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-03-09","conditions":"Breast Cancer","enrollment":252},{"nctId":"NCT05203562","phase":"PHASE2, PHASE3","title":"Letrozole as a Prophylaxis From GTN for Complete Mole Patients","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2020-06-01","conditions":"Gestational Trophoblastic Disease","enrollment":200},{"nctId":"NCT00828854","phase":"PHASE2","title":"Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-10-01","conditions":"ER+ Breast Cancer","enrollment":27},{"nctId":"NCT03009838","phase":"PHASE3","title":"Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-01-02","conditions":"Infertility","enrollment":150},{"nctId":"NCT01587040","phase":"PHASE1, PHASE2","title":"Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07-20","conditions":"Neoplasm Malignant","enrollment":61},{"nctId":"NCT05167643","phase":"NA","title":"H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-01-23","conditions":"Advanced HR+ HER2 Negative Breast Carcinoma","enrollment":40},{"nctId":"NCT03625531","phase":"PHASE3","title":"A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS","status":"UNKNOWN","sponsor":"Hongxia Ma","startDate":"2018-08-13","conditions":"Polycystic Ovary Syndrome","enrollment":1100},{"nctId":"NCT05198141","phase":"PHASE4","title":"Evaluation of Different Doses of Letrozole in Ectopic Pregnancy","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-12-15","conditions":"Ectopic Pregnancy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Femara","Placebo"],"phase":"phase_3","status":"active","brandName":"Letrozole Oral Tablet","genericName":"Letrozole Oral Tablet","companyName":"Eastern Virginia Medical School","companyId":"eastern-virginia-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Letrozole Oral Tablet is a small molecule inhibitor of the cytochrome P450 19A1 enzyme, specifically targeting aromatase. It has been studied for various conditions, including male reproductive problems, infertility, breast cancer, female infertility, and polycystic ovary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}